在甲状腺癌中准内皮生长因子受体:当前的概念和未来的方向
Nastaran Masoudi-Khoram1,2, Sara Cheraghi2, Mahboobeh Nazari3
1Cancer Control Research Center, Cancer Control Foundation, Iran University of Medical Sciences, Tehran, Iran.
Medical oncology (Northwood, London, England)
|June 2, 2025
概括
甲状腺癌 (TC) 发病率正在上升,晚期病例带来治疗挑战. 本综述探讨了针对表皮生长因子受体 (EGFR) 途径,以改善甲状腺癌治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 甲状腺癌 (TC) 是一种全球普遍存在的恶性瘤,发病率不断增加.
- 虽然差异化TC通常是可以治疗的,但晚期或转移性病例,特别是放射性耐药性瘤,存在重大管理挑战.
- 皮表皮生长因子受体 (EGFR) 信号通路与癌细胞增殖,分化和迁移有关,并且在甲状腺癌中经常过度表达.
研究的目的:
- 为了阐明EGFR信号通路在甲状腺癌中的功能意义.
- 在甲状腺癌治疗中审查针对EGFR的当前治疗策略.
主要方法:
- 对调查甲状腺癌EGFR信号传递的研究进行文献综述.
- 对当前针对性治疗方法的分析,包括针对EGFR的单克隆抗体和氨酸激酶抑制剂.
主要成果:
- 在甲状腺癌中EGFR过度表达,表明其作为治疗点的潜力.
- 目前正在探索针对性疗法,如抗EGFR单克隆抗体和EGFR氨酸激酶抑制剂,用于TC治疗.
结论:
- EGFR信号通路在甲状腺癌的进展中起着关键作用.
- 向EGFR是一个有前途的策略,用于管理先进和耐药的甲状腺癌.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Transducer Mechanism: Enzyme-Linked Receptors
2.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.9K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Synthesis and Regulation of Thyroid Hormones
5.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263


